Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30

Glueck, Charles J.; Fontaine, R; Wang, Ping; Subbiah, M.T.R.; Weber, Karen; Illig, Ellen; Streicher, Patricia; Sieve-Smith, Luann; Tracy, Trent; Lang, James E.; McCullough, Pamela A.

doi:10.1053/meta.2001.24192

Cited by 167 publications

(110 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unlike other pharmacological therapies for type 2 diabetes (sulfonylureas or insulin) metformin treatments are not associated with weight gain. Consistently, clinical studies have shown a significant decrease in body weight (24,25). Metformin treatment resulted in 1.5 kg weight loss during 6 months, suggesting marked anorectic effects on hyperphagia associated in this case with deficient leptin signaling, rather than a mere improvement in insulin sensitivity.…”

Section: Discussionsupporting

confidence: 70%

Markedly Improved Glycemic Control and Enhanced Insulin Sensitivity in a Patient with Type 2 Diabetes Complicated by a Suprasellar Tumor Treated with Pioglitazone and Metformin

2005

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 70%

Markedly Improved Glycemic Control and Enhanced Insulin Sensitivity in a Patient with Type 2 Diabetes Complicated by a Suprasellar Tumor Treated with Pioglitazone and Metformin

2005

View full text Add to dashboard Cite

show abstract

“…[79][80][81][82] The first Biguanides and Prevention of the Risks in Obesity study 1 enrolled 324 patients with abdominal obesity (waist-hip ratio X0.95 in men and X0.80 in women) in order to recruit a trial population containing a high prevalence of insulin resistance. 79 Subjects were also free of cardiovascular disease and diabetes at baseline.…”

Section: Effects Of Metformin On Body Weight In Nondiabetic Patientsmentioning

confidence: 99%

Metformin and body weight

2007

View full text Add to dashboard Cite

Most patients with type 2 diabetes are overweight or obese, overweight or obesity increases the risk of developing type 2 diabetes and obesity per se is strongly associated with multiple cardiometabolic risk factors. However, many antidiabetic treatments increase body weight. The oral antidiabetic agent, metformin, has been evaluated in hundreds of clinical studies in diverse patient populations during approximately five decades of clinical use. This review summarizes the effects of metformin on body weight, with special reference to studies of longer duration (X6 months) as both diabetes and obesity are long-term conditions. Approximately half of studies in drug-naive type 2 diabetic patients demonstrated significant weight loss with metformin compared with baseline or comparator drugs, although pooled analyses have suggested no significant effect versus placebo. Similarly, metformin has been shown to induce weight loss in obese nondiabetic populations, although studies of long duration in this population are scarce. Metformin does appear to mitigate the adverse effects of insulin on body weight. The weight-neutral or weight-sparing effects of metformin constitute a therapeutic advantage in diabetes management where other first-line oral antidiabetic treatments often promote clinically significant weight gain.

show abstract

“…Metformin is known and widely used throughout the world for its antidiabetic action, but has gained importance by other effects [4]: reduces food intake and weight, influence cardiovascular risk markers, inflammatory markers and possibly reduces the risk of cancer [5].…”

Section: Metforminmentioning

confidence: 99%

Diabetes-Old Therapies Revisited

Guimarães¹

2016

EMIJ

View full text Add to dashboard Cite

Today, there are many therapeutic options for the treatment of type 2 Diabetes, which means that therapeutic decision making has become increasingly challenging and complex. With the recent introduction in clinical practice of new classes, with different mechanisms of action, what is the role of the older drugs? This article reviews these drugs, with recently published data update. Today, recommendations are not based on a simple algoritm, but in a patient centered approach. Besides the phenotypic heterogeneity of patients with type 2 diabetes, there is also a great diversity in response to treatment. This concept of personalized medicine has changed in recent years. The new era of personalized medicine evolves in order to identify molecular and clinical signs that can predict therapeutic response, reducing uncertainty in decision making. The "old" drugs may resurface, with more precise indications, in selected groups of patients.

show abstract

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30

Cited by 167 publications

References 31 publications

Markedly Improved Glycemic Control and Enhanced Insulin Sensitivity in a Patient with Type 2 Diabetes Complicated by a Suprasellar Tumor Treated with Pioglitazone and Metformin

Markedly Improved Glycemic Control and Enhanced Insulin Sensitivity in a Patient with Type 2 Diabetes Complicated by a Suprasellar Tumor Treated with Pioglitazone and Metformin

Metformin and body weight

Diabetes-Old Therapies Revisited

Contact Info

Product

Resources

About